Higher mortality of COVID-19 patients with comorbidity is the formidable challenge faced by the health care system. In response to the present crisis, understanding the molecular basis of comorbidity is essential to accelerate the development of drugs. To address this, the genetic association between COVID-19 and various lung disorders was measured and notable molecular resemblance was observed. 141 lung diseases were linked to a neighborhood network of SARS-CoV-2 targets, and 59 lung diseases topologically overlapped with COVID-19 module. This demonstrates the clustering of lung diseases with COVID-19 in the same network vicinity, indicating the potential threat for lung patients upon SARS-CoV-2 infection. Pathobiological similarities between lung diseases and COVID-19, and clinical evidences suggest that shared molecular features probably the reason for comorbidity. Additionally, topological overlap with various lung disorders provides an opportunity to repurpose the drugs used for lung disease to hit the closely associated COVID-19 module. Further analysis showed that the functional protein-protein interaction modules in the lungs, substantially hijacked by SARS-CoV-2, were connected to several lung disorders. The network-based proximity measure identified the FDA approved targets in hijacked protein modules which can be hit by existing drugs to rescue these modules from viral possessions, and can lead to the improvement of clinical conditions.